(Medical Xpress) -- Australian researchers have found biomarkers in the blood that could help develop a test to identify people in the early stages of Alzheimers disease.
University of New South Wales School of Psychiatry Professor Perminder Sachdev and his team looked at apolipoproteins, which transport cholesterol in the blood, and found they were dysregulated or abnormal in patients with mild cognitive impairment. The research findings are published in the journal PLOS ONE.
Essentially, this is one step towards developing a suite of biomarkers to include a number of different proteins that will identify individuals with mild cognitive impairment who will probably go on to develop Alzheimers disease or dementia in the future, Professor Sachdev says.
Evidence suggests these proteins are involved in Alzheimers disease and some other brain diseases, Professor Sachdev says.
The researchers examined the group of apolipoproteins in the blood of more than 1,000 study participants over a two-year period. About half of the group also had Magnetic Resonance Imaging brain scans and were rated according to their cognitive impairment.
Apolipoproteins have been of interest in Alzheimers disease for a number of reasons, Professor Sachdev says.
It is know that one variant of the gene for one type of apolipoprotein, Apo E, increases the risk of Alzheimers. Another of these proteins, Apo J or clusterin, has been found in the brain lesions of people with Alzheimers.
We found abnormal levels of clusterin but also some other apolipoproteins in the blood of older individuals with memory problems, and these levels tended to predict who showed worsening of their mental functions over two years.
As early indicators of cognitive decline, these apolipoproteins may also become targets of treatment or preventative healthcare measures, the authors say.
Explore further: High blood pressure associated with risk for mild cognitive impairment